Patents by Inventor Ralph Weissleder

Ralph Weissleder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210080390
    Abstract: The disclosure features systems and methods for measuring and diagnosing target constituents bound to labeling particles in a sample. The systems include a radiation source, a sample holder, a detector configured to obtain one or more diffraction patterns of the sample each including information corresponding to optical properties of sample constituents, and an electronic processor configured to, for each of the one or more diffraction patterns: (a) analyze the diffraction pattern to obtain amplitude information and phase information corresponding to the sample constituents; (b) identify one or more particle-bound target sample constituents based on at least one of the amplitude information and the phase information; and (c) determine an amount of at least one of the particle-bound target sample constituents in the sample based on at least one of the amplitude information and the phase information.
    Type: Application
    Filed: July 27, 2020
    Publication date: March 18, 2021
    Inventors: Ralph Weissleder, Hakho Lee, Hyungsoon Im, Cesar Castro
  • Publication number: 20210038748
    Abstract: This document relates to compounds useful for targeting PARP1. Also provided herein are methods for using such compounds to detect and image cancer cells.
    Type: Application
    Filed: May 14, 2020
    Publication date: February 11, 2021
    Inventors: Thomas Reiner, Edmund J. Keliher, Ralph Weissleder
  • Publication number: 20200408687
    Abstract: In an exemplary method, a sample is provided. The sample contains a polymerase molecule, a receptor molecule containing a fluorophore, and a detector molecule. The detector molecule is configured to, in the presence of a target nucleic acid, inhibit the polymerase molecule from cleaving the fluorophore. A level of fluorescence anisotropy from the sample is detected to determine the absence or presence of the target nucleic acid in the sample.
    Type: Application
    Filed: March 27, 2017
    Publication date: December 31, 2020
    Inventors: Ralph Weissleder, Hakho Lee, Kisoo Park, Chen-han Huang
  • Publication number: 20200384137
    Abstract: The present invention, in some aspects, provides methods, reagents, compositions, and kits for the radiolabeling of proteins, for example, of proteins useful for positron emission tomography (PET) or single-photon emission computed tomography (SPECT) (e.g., for diagnostic and therapeutic applications), using sortase-mediated transpeptidation reactions. Some aspects of this invention provide methods for the conjugation of an agent, for example, a radioactive agent or molecule to diagnostic or therapeutic peptides or proteins. Compositions comprising sortagged, radiolabeled proteins as well as reagents for generating radiolabeled proteins are also provided. Kits comprising reagents useful for the generation of radiolabeled proteins are provided, as are precursor proteins that comprise a sortase recognition motif.
    Type: Application
    Filed: January 8, 2020
    Publication date: December 10, 2020
    Applicants: Whitehead Institute for Biomedical Research, The General Hospital Corporation
    Inventors: Mohammad Rashidian, Hidde L. Ploegh, Ralph Weissleder, Edmund J. Keliher
  • Publication number: 20200338011
    Abstract: Disclosed herein are nanoparticles that include one or more cyclodextrin moieties crosslinked by a linker. The cyclodextrin moieties can complex therapeutic (e.g., anticancer) agents, and can be used to treat diseases such as cancer.
    Type: Application
    Filed: October 19, 2018
    Publication date: October 29, 2020
    Inventors: Christopher Rodell, Ralph Weissleder
  • Publication number: 20200289667
    Abstract: Compositions comprising a macrophage-targeted carrier and one or more therapeutic agents that modulate cardiac conductance, and methods of using the same for treating subjects with cardiac rhythm disorders, e.g., bradycardia or tachycardia.
    Type: Application
    Filed: June 1, 2020
    Publication date: September 17, 2020
    Inventors: Maarten Hulsmans, Matthias Nahrendorf, Ralph Weissleder
  • Patent number: 10724948
    Abstract: The disclosure features systems and methods for measuring and diagnosing target constituents bound to labeling particles in a sample. The systems include a radiation source, a sample holder, a detector configured to obtain one or more diffraction patterns of the sample each including information corresponding to optical properties of sample constituents, and an electronic processor configured to, for each of the one or more diffraction patterns: (a) analyze the diffraction pattern to obtain amplitude information and phase information corresponding to the sample constituents; (b) identify one or more particle-bound target sample constituents based on at least one of the amplitude information and the phase information; and (c) determine an amount of at least one of the particle-bound target sample constituents in the sample based on at least one of the amplitude information and the phase information.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: July 28, 2020
    Assignee: The General Hospital Corporation
    Inventors: Ralph Weissleder, Hakho Lee, Hyungsoon Im, Cesar Castro
  • Patent number: 10712343
    Abstract: This invention relates to methods for diagnosing cancer, e.g., cancer of epithelial origin, by detecting the presence of tumor cells in a sample, based (at least in some embodiments) on the quantification of levels of four biomarkers, MUC1, EGFR, EpCAM, and HER2. In some embodiments, the methods are performed using diagnostic magnetic resonance (DMR), e.g., with a portable relaxometer or MR imager.
    Type: Grant
    Filed: January 9, 2017
    Date of Patent: July 14, 2020
    Assignee: The General Hospital Corporation
    Inventors: Ralph Weissleder, Hakho Lee, Cesar Castro
  • Publication number: 20200199085
    Abstract: The present application relates to functionalized 1,2,4,5-tetrazine compounds. The compounds are useful in compositions and methods using bioorthogonal inverse electron demand Diels-Alder cycloaddition reactions for the rapid and specific covalent delivery of a “payload” to a ligand bound to a biological target.
    Type: Application
    Filed: March 2, 2020
    Publication date: June 25, 2020
    Inventors: Scott A. Hilderbrand, Neal K. Devaraj, Ralph Weissleder, Mark R. Karver
  • Publication number: 20200188535
    Abstract: This present application relates to fluorescent tetrazine-containing compounds consisting of a single pi-system. For example, a compound of Formula (I): F-L-Tz or a salt thereof, wherein: F is a fluorophore, L is a conjugated linker, and Tz is a substituted or unsubstituted tetrazine; wherein the linker bridges the Tz and F moieties in a single conjugated pi-system. Also provided herein are methods of using the compounds provided herein for biomedical imaging.
    Type: Application
    Filed: December 16, 2019
    Publication date: June 18, 2020
    Inventors: Labros Meimetis, Jonathan Carlson, Ralph Weissleder
  • Patent number: 10653805
    Abstract: This document relates to compounds useful for targeting PARP1. Also provided herein are methods for using such compounds to detect and image cancer cells.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: May 19, 2020
    Assignee: The General Hospital Corporation
    Inventors: Thomas Reiner, Edmund J. Keliher, Ralph Weissleder
  • Patent number: 10655163
    Abstract: Described herein are methods, compositions, kits and systems for multiplexed detection of target molecules from a sample. In some embodiments, the methods, compositions, kits and systems can be used to perform multiplexed protein analysis of a sample (e.g., a sample comprising a small number of cells or a single-cell sample). In some embodiments, the same sample subjected to a multiplexed protein analysis using the methods, compositions, kits and systems described herein can also be subjected to a nucleic acid (e.g., RNAs, microRNAs, and/or DNA) analysis, thereby creating an integrated expression profiling from a limited amount of sample.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: May 19, 2020
    Assignee: THE GENERAL HOSPITAL CORPORATION
    Inventors: Ralph Weissleder, Sarit S. Agasti, Vanessa M. Peterson, Adeeti Ullal
  • Patent number: 10611738
    Abstract: The present application relates to functionalized 1,2,4,5-tetrazine compounds. The compounds are useful in compositions and methods using bioorthogonal inverse electron demand Diels-Alder cycloaddition reactions for the rapid and specific covalent delivery of a “payload” to a ligand bound to a biological target.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: April 7, 2020
    Assignee: The General Hospital Corporation
    Inventors: Scott A. Hilderbrand, Neal K. Devaraj, Ralph Weissleder, Mark R. Karver
  • Publication number: 20200095323
    Abstract: Fc-engineered variants of anti-PD1 IgG antibodies that abrogate Fc?R binding and mAb effector functions, or combinations with therapies that inhibit Fc?R binding in vivo, for treatment of cancer.
    Type: Application
    Filed: March 19, 2018
    Publication date: March 26, 2020
    Inventors: Mikael J. Pittet, Ralph Weissleder, Sean Arlauckas, Christopher Garris
  • Patent number: 10557847
    Abstract: Disclosed herein are compositions and methods for exosome detection with high sensitivity by using a nano-plasmonic sensor. The nano-plasmonic sensor comprises a plurality of nanoapertures suitable for transmission measurements. The detection sensitivity is on the order of 104-fold higher than western blotting and 102-fold higher than enzyme-linked immunosorbent assay (ELISA). A portable imaging system is also disclosed, enabling rapid and high-throughput detection of exosomes. The nano-plasmonic sensor and imaging system can be useful in diagnostics.
    Type: Grant
    Filed: December 2, 2014
    Date of Patent: February 11, 2020
    Assignee: THE GENERAL HOSPITAL CORPORATION
    Inventors: Ralph Weissleder, Hakho Lee, Hyungsoon Im, Cesar Castro
  • Patent number: 10556024
    Abstract: The present invention, in some aspects, provides methods, reagents, compositions, and kits for the radiolabeling of proteins, for example, of proteins useful for positron emission tomography (PET) or single-photon emission computed tomography (SPECT) (e.g., for diagnostic and therapeutic applications), using sortase-mediated transpeptidation reactions. Some aspects of this invention provide methods for the conjugation of an agent, for example, a radioactive agent or molecule to diagnostic or therapeutic peptides or proteins. Compositions comprising sortagged, radiolabeled proteins as well as reagents for generating radiolalebed proteins are also provided. Kits comprising reagents useful for the generation of radiolabeled proteins are provided, as are precursor proteins that comprise a sortase recognition motif.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: February 11, 2020
    Assignees: Whitehead Institute for Biomedical Research, The General Hospital Corporation
    Inventors: Mohammad Rashidian, Hidde L. Ploegh, Ralph Weissleder, Edmund J. Keliher
  • Patent number: 10517965
    Abstract: This present application relates to fluorescent tetrazine-containing compounds consisting of a single pi-system. For example, a compound of Formula (I): or a salt thereof, wherein: F is a fluorophore, L is a conjugated linker, and Tz is a substituted or unsubstituted tetrazine; wherein the linker bridges the Tz and F moieties in a single conjugated pi-system. Also provided herein are methods of using the compounds provided herein for biomedical imaging.
    Type: Grant
    Filed: May 6, 2014
    Date of Patent: December 31, 2019
    Assignee: The General Hospital Corporation
    Inventors: Labros Meimetis, Jonathan Carlson, Ralph Weissleder
  • Publication number: 20190346434
    Abstract: Target analyte detection devices include a housing having a potentiostat and a microcontroller coupled to the potentiostat. The device also includes a substrate having a plurality of electrodes on a first surface of the substrate. A first set of electrodes of the plurality of electrodes defines a first sample detection region. The substrate is removably attachable to the housing such that the first set of electrodes is coupled to the potentiostat upon attaching the substrate to the housing. The device also includes a magnet assembly couplable to a second surface of the substrate. The magnet assembly includes a magnet positioned in the magnet assembly such that a magnetic field from the magnet extends through the substrate and the first set of electrodes into an area above the first sample detection region upon coupling the magnet assembly to the substrate.
    Type: Application
    Filed: January 27, 2017
    Publication date: November 14, 2019
    Inventors: Hakho Lee, Ralph Weissleder, Sangmoo Jeong, Jongmin Park, Caesar Castro, Hsing-Ying Lin, Jamil Azzi
  • Publication number: 20190256888
    Abstract: Described herein are methods, compositions, kits and systems for multiplexed detection of target molecules from a sample. In some embodiments, the methods, compositions, kits and systems can be used to perform multiplexed protein analysis of a sample (e.g., a sample comprising a small number of cells or a single-cell sample). In some embodiments, the same sample subjected to a multiplexed protein analysis using the methods, compositions, kits and systems described herein can also be subjected to a nucleic acid (e.g., RNAs, microRNAs, and/or DNA) analysis, thereby creating an integrated expression profiling from a limited amount of sample.
    Type: Application
    Filed: March 4, 2019
    Publication date: August 22, 2019
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventors: Ralph WEISSLEDER, Sarit S. AGASTI, Vanessa M. PETERSON, Adeeti ULLAL
  • Patent number: 10357574
    Abstract: The present invention provides methods and compositions based on optical sensor conjugates that are useful for detecting reactive oxygen, reactive nitrogen, or both species that are a direct result of inflammation caused by tissue damage.
    Type: Grant
    Filed: May 1, 2017
    Date of Patent: July 23, 2019
    Assignee: The General Hospital Corporation
    Inventors: Scott A. Hilderbrand, Ralph Weissleder, Peter Panizzi, Jason R. McCarthy